Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes

December 2020

You'll start to see more patients who DON'T have diabetes using SGLT2 inhibitors (Invokana, etc) for heart failure or kidney disease.

That's because evidence suggests these meds may improve outcomes when added to standard therapy.

For example, in some heart failure patients, adding Farxiga (dapagliflozin) or Jardiance (empagliflozin) may prevent hospitalization or cardiovascular (CV) death.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote